Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...
Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.
ManaMed LLC, a global leader in orthopedic mobility and post-operative rehabilitation equipment, is thrilled to announce the launch of three groundbreaking products designed to enhance patient care.
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...
The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome ...
Arrowhead’s plozasiran, meanwhile, showed its worth in the phase 2b SHASTA-2 study in severe HTG patients at risk of acute pancreatitis, with an average 74% reduction in triglyceride levels at ...
There is potential competition on the way from Arrowhead Pharma, whose plozasiran was submitted for approval with the FDA as a treatment for FCS in November.